CXCR4-targeting nanobodies differentially inhibit CXCR4 function and HIV entry.
Van Hout A, Klarenbeek A, Bobkov V, Doijen J, Arimont M, Zhao C, Heukers R, Rimkunas R, de Graaf C, Verrips T, van der Woning B, de Haard H, Rucker JB, Vermeire K, Handel T, Van Loy T, Smit MJ, Schols D.
Van Hout A, et al. Among authors: bobkov v.
Biochem Pharmacol. 2018 Dec;158:402-412. doi: 10.1016/j.bcp.2018.10.015. Epub 2018 Oct 17.
Biochem Pharmacol. 2018.
PMID: 30342024